Editors:
Host-directed therapy is a unique, innovative, and burgeoning new approach for the treatment of infectious diseases, and specifically for tuberculosis, the leading cause of death by a single infectious agent. As a new field, no similar comprehensive survey of completed and ongoing research exists
Each section of the text contains several chapters written by a top expert in that specific area. The information provided represents a thorough and state-of-the-art analysis of the field
The implications for host responses and pathways are of broad interest in physiology and in various diseases of non-infectious origin (e.g, autoimmunity, cancer, metabolic disorders), or those that can be exploited for treating infectious diseases other than tuberculosis
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (22 chapters)
-
Front Matter
-
Introduction
-
Front Matter
-
-
Targeting Immunometabolism
-
Front Matter
-
-
Enhancing Anti-mycobacterial Mechanisms
-
Front Matter
-
-
Targeting Immune Cells
-
Front Matter
-
About this book
Editors and Affiliations
-
Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, USA
Petros C. Karakousis
-
Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, Rockville, USA
Richard Hafner
-
Public Health Research Institute New Jersey Medical School Rutgers Biomedical and Health Sciences, Rutgers-The State University of New Jersey, Newark, USA
Maria Laura Gennaro
About the editors
Petros C. Karakousis, M.D., is an infectious diseases-trained physician scientist and Professor of Medicine at the Johns Hopkins University School of Medicine. His research focus is on host-pathogen interactions contributing to Mycobacterium tuberculosis persistence and antibiotic tolerance. His laboratory is actively investigating the repurposing of clinically available agents with immune-modulatory properties as adjunctive host-directed therapy, in order to shorten the duration of TB treatment and improve lung pathology.
Maria Laura Gennaro, M.D., is Professor of Medicine at Rutgers New Jersey School of Medicine. Her laboratory studies mechanisms of adaptation expressed by Mycobacterium tuberculosis and by the host macrophage during infection, with the goal of finding targets for therapeutic intervention. She has a specific interest in macrophage lipid metabolism, which is altered following M. tuberculosis infection, thereby promoting bacterial survival.
Richard Hafner, M.D., is an infectious diseases-trained physician and Chief of the TB Clinical Research Branch in the Division of AIDS at NIAID/NIH. Throughout his career, he has had a long-standing interest in advancing innovative host-directed therapies for infections. He has been involved in several clinical trials, authored various articles, and hosted multiple scientific meetings related to research to develop targeted HDTs for TB.
Bibliographic Information
Book Title: Advances in Host-Directed Therapies Against Tuberculosis
Editors: Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro
DOI: https://doi.org/10.1007/978-3-030-56905-1
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Nature Switzerland AG 2021
Hardcover ISBN: 978-3-030-56904-4Published: 04 December 2020
Softcover ISBN: 978-3-030-56907-5Published: 04 December 2021
eBook ISBN: 978-3-030-56905-1Published: 03 December 2020
Edition Number: 1
Number of Pages: XIII, 332
Number of Illustrations: 20 b/w illustrations
Topics: Immunology, Infectious Diseases, Pharmacotherapy